Arcus Biosciences (RCUS) Fundamental Analysis: Revenue, Earnings & Valuation

4.89 / 10

Netural

Fundamental analysis rates RCUS at 4.9/10, showing modest strength. Cash‑to‑market and inventory turnover are strong, while asset‑to‑market is positive. Revenue‑to‑market and YoY revenue growth are negative, and income‑tax ratio is zero, leading to a neutral overall view.

Analysis Checks(7/10)

Revenue-MV

Value-2.25

Score1/3

Weight12.23%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value-4.26

Score2/3

Weight-1.96%

1M Return-1.06%

Inventory turnover ratio

Value103.94

Score3/3

Weight16.22%

1M Return6.74%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.70%

1M Return1.69%

PB-ROE

Value1.15

Score1/3

Weight13.59%

1M Return5.29%

Income tax / Total profit (%)

Value0.00

Score1/3

Weight-0.94%

1M Return-0.50%

Fixed assets turnover ratio

Value5.68

Score2/3

Weight-1.08%

1M Return-0.51%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight9.38%

1M Return4.32%

Asset-MV

Value-0.55

Score3/3

Weight34.44%

1M Return11.84%

Cash-MV

Value0.02

Score2/3

Weight14.41%

1M Return5.94%

Is RCUS undervalued or overvalued?

RCUS scores 4.89/10 on fundamentals and holds a Fair valuation at present. Backed by its -63.26% ROE, -142.91% net margin, -8.32 P/E ratio, 4.65 P/B ratio, and -4.78% earnings growth, these metrics solidify its Netural investment rating.